Cargando…

Considerations for the US health-system pharmacist in a world of biosimilars

As numerous biosimilar products are forecast to enter the US market in the coming years, health-system pharmacists will be faced with novel challenges while incorporating them into clinical practice. The current regulatory approval framework and guidance from the US Food and Drug Administration do n...

Descripción completa

Detalles Bibliográficos
Autores principales: Zlatkus, Andrea, Bixby, Todd, Goyal, Kavitha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioExcel Publishing Ltd 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7048155/
https://www.ncbi.nlm.nih.gov/pubmed/32158487
http://dx.doi.org/10.7573/dic.2019-12-1
_version_ 1783502251855183872
author Zlatkus, Andrea
Bixby, Todd
Goyal, Kavitha
author_facet Zlatkus, Andrea
Bixby, Todd
Goyal, Kavitha
author_sort Zlatkus, Andrea
collection PubMed
description As numerous biosimilar products are forecast to enter the US market in the coming years, health-system pharmacists will be faced with novel challenges while incorporating them into clinical practice. The current regulatory approval framework and guidance from the US Food and Drug Administration do not address many real-world scenarios that pharmacists will encounter. We provide an overview of the evolving healthcare landscape shaped by the entry of multiple biosimilars, including for a given reference product, and their impact on the health-system pharmacist with respect to formulary assessment, implementation, and education of various health-system stakeholders, including patients.
format Online
Article
Text
id pubmed-7048155
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioExcel Publishing Ltd
record_format MEDLINE/PubMed
spelling pubmed-70481552020-03-10 Considerations for the US health-system pharmacist in a world of biosimilars Zlatkus, Andrea Bixby, Todd Goyal, Kavitha Drugs Context Editorial As numerous biosimilar products are forecast to enter the US market in the coming years, health-system pharmacists will be faced with novel challenges while incorporating them into clinical practice. The current regulatory approval framework and guidance from the US Food and Drug Administration do not address many real-world scenarios that pharmacists will encounter. We provide an overview of the evolving healthcare landscape shaped by the entry of multiple biosimilars, including for a given reference product, and their impact on the health-system pharmacist with respect to formulary assessment, implementation, and education of various health-system stakeholders, including patients. BioExcel Publishing Ltd 2020-02-25 /pmc/articles/PMC7048155/ /pubmed/32158487 http://dx.doi.org/10.7573/dic.2019-12-1 Text en Copyright © 2020 Zlatkus A, Bixby T, Goyal K. Published by Drugs in Context under Creative Commons License Deed CC BY NC ND 4.0 which allows anyone to copy, distribute, and transmit the article provided it is properly attributed in the manner specified below. No commercial use without permission.
spellingShingle Editorial
Zlatkus, Andrea
Bixby, Todd
Goyal, Kavitha
Considerations for the US health-system pharmacist in a world of biosimilars
title Considerations for the US health-system pharmacist in a world of biosimilars
title_full Considerations for the US health-system pharmacist in a world of biosimilars
title_fullStr Considerations for the US health-system pharmacist in a world of biosimilars
title_full_unstemmed Considerations for the US health-system pharmacist in a world of biosimilars
title_short Considerations for the US health-system pharmacist in a world of biosimilars
title_sort considerations for the us health-system pharmacist in a world of biosimilars
topic Editorial
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7048155/
https://www.ncbi.nlm.nih.gov/pubmed/32158487
http://dx.doi.org/10.7573/dic.2019-12-1
work_keys_str_mv AT zlatkusandrea considerationsfortheushealthsystempharmacistinaworldofbiosimilars
AT bixbytodd considerationsfortheushealthsystempharmacistinaworldofbiosimilars
AT goyalkavitha considerationsfortheushealthsystempharmacistinaworldofbiosimilars